DALLA EVIDENCE-BASED MEDICINE ALLA EGO-BASED MEDICINE? UNA OPPORTUNA RIFLESSIONE DI ANTONIO ADDIS DOPO IL COVID-19 (FREE).

Ego Based Medicine Antonio Addis Ho il timore che tra le tante vittime del Covid-19 vada annoverata anche l’evidence based medicine (EBM). Probabilmente anche prima dell’emergenza non godeva di ottima salute, ma la recente pandemia sembra averle dato un colpo definitivo, almeno per quanto riguarda l’ambito regolatorio. L’approccio metodologico che ha rivoluzionato il processo decisionale…

PANCREATITE ACUTA: MA QUANTI LIQUIDI PER EVITARE UN SOVRACCARICO? IL TRIAL WATERFALL DAL “NEJM”.

Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis Enrique de-Madaria et al. Abstract BACKGROUND Early aggressive hydration is widely recommended for the management of acute pancreatitis, but evidence for this practice is limited. METHODS At 18 centers, we randomly assigned patients who presented with acute pancreatitis to receive goal-directed aggressive or moderate resuscitation with lactated…

TRIAL OGGI ? USATA LA LIKELIHOOD RATIO INVECE DEL RISCHIO RELATIVO! INTERESSANTE … DA “BMJ Evidence-Based Medicine”.

Likelihood ratio interpretation of the relative risk Suhail A R Doi et al. Interpreting diagnostic test results in medicine The likelihood ratio (LR) is today commonly used in medicine for diagnostic inference. Historically, it was preceded by introduction, in 1966, of the predictive value of a diagnostic test in Medicine1 and within a decade of the…

RIFAXIMINA E SIMVASTATINA MIGLIORANO IL PROFILO PLASMATICO DEI METABOLITI IN CORSO DI CIRROSI SCOMPENSATA. DA “Hepatology Communications” (FREE).

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis Elisa Pose, et al. Abstract Patients with decompensated cirrhosis, particularly those with acute‐on‐chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma…

RIFAXIMINA + LUBIPROSTONE: RIDUZIONE DELLA FIBROSI VIA RIPARAZIONE DELLA BARRIERA MUCOSA. UN MODELLO ANIMALE DA SEGUIRE

Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis Masahide Enomoto et al. Abstract Background Although gut-derived lipopolysaccharide (LPS) affects the progression of non-alcoholic steatohepatitis (NASH) pathogenesis, few studies have focused on this relationship to develop treatments for NASH. Aims To explore the effects of combination with rifaximin…

STANDARD CONSIGLIATO PER I TRIAL SUL CANCRO DEL PANCREAS , RESECABILE, O BORDERLINE RESECABILE. UN IMPORTANTE CONSENSUS STATEMENT DA “JAMA SURGERY” .

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). A Systematic Review and Delphi Consensus Statement. Esther N. Pijnappel et al. Abstract Importance  Pancreatic cancer is the third most common cause of cancer death; however, randomized clinical trials (RCTs) of survival in patients with resectable pancreatic cancer…